Are early and late cardiovascular risk markers in women with polycystic ovary syndrome increased with concomitant non-alcoholic steatohepatitis and can this be modified with liraglutide?

Trial Profile

Are early and late cardiovascular risk markers in women with polycystic ovary syndrome increased with concomitant non-alcoholic steatohepatitis and can this be modified with liraglutide?

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Oct 2014

At a glance

  • Drugs Liraglutide (Primary) ; Metformin
  • Indications Polycystic ovary syndrome
  • Focus Pharmacodynamics
  • Most Recent Events

    • 09 Oct 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2009-015927-94).
    • 31 Dec 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 25 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top